Back to search

Article

Genetic surveillance of SARS-CoV-2 M <sup>pro</sup> reveals high sequence and structural conservation prior to the introduction of protease inhibitor Paxlovid

2022-03-30

Abstract excerpt

SARS-CoV-2 continues to represent a global health emergency as a highly transmissible, airborne virus. An important coronaviral drug target for treatment of COVID-19 is the conserved main protease (M pro ). Nirmatrelvir is a potent M pro inhibitor and the antiviral component of Paxlovid™. The significant viral sequencing effort during the ongoing COVID-19 pandemic represented a unique opportunity to assess poten...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
9ffaffac-66ff-5195-8350-cea219832717
DOI
10.1101/2022.03.29.486331
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Genetic surveillance of SARS-CoV-2 M <sup>pro</sup> reveals high sequence and structural conservation prior to the introduction of protease inhibitor PaxlovidDOI 10.1101/2022.03.29.486331
Genetic Surveillance of SARS-CoV-2 M pro Reveals High Sequence and Structural Conservation Prior to the Introduction of Protease Inhibitor PaxlovidSemantic proximity
Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitorsSemantic proximity
Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir (PF-07321332)Semantic proximity
Changes in the mutational dynamics of the SARS-CoV-2 main-protease substantiate the danger of emerging resistance to antiviral drugs.Semantic proximity
A comprehensive study of SARS-CoV-2 main protease (M <sup>pro</sup> ) inhibitor-resistant mutants selected in a VSV-based systemSemantic proximity
Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvirSemantic proximity
Monitoring for SARS-CoV-2 drug resistance mutations in broad viral populationsSemantic proximity
Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of NirmatrelvirSemantic proximity
Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitorsSemantic proximity
A proof-of-concept study on the genomic evolution of Sars-Cov-2 in molnupiravir-treated, paxlovid-treated and drug-naïve patientsSemantic proximity
Genomic Evolution of Sars-Cov-2 in Molnupiravir-Treated Patients Compared to Paxlovid-Treated and Drug-Naïve Patients: A Proof-of-Concept StudySemantic proximity
Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to NirmatrelvirSemantic proximity
Select a neighboring publication to make it the new centre.